Concert Pharmaceuticals Inc. (NASDAQ:CNCE) rose 2.6% during mid-day trading on Friday . The company traded as high as $11.84 and last traded at $11.49, with a volume of 57,004 shares changing hands. The stock had previously closed at $11.20.

CNCE has been the topic of a number of recent analyst reports. Brean Capital restated a “buy” rating on shares of Concert Pharmaceuticals in a research note on Saturday, April 30th. Zacks Investment Research upgraded shares of Concert Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, May 4th. Finally, Stifel Nicolaus began coverage on shares of Concert Pharmaceuticals in a research note on Friday, July 1st. They set a “buy” rating and a $23.00 price objective on the stock. Two analysts have rated the stock with a sell rating and six have given a buy rating to the company. Concert Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $26.43.

The company has a 50-day moving average of $11.94 and a 200-day moving average of $13.53. The stock has a market capitalization of $258.15 million and a PE ratio of 13.95.

Concert Pharmaceuticals (NASDAQ:CNCE) last posted its earnings results on Thursday, May 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by $0.18. On average, equities analysts forecast that Concert Pharmaceuticals Inc. will post ($2.16) earnings per share for the current year.

In other news, CEO Roger D. Tung bought 19,610 shares of the stock in a transaction that occurred on Wednesday, May 11th. The shares were acquired at an average cost of $10.55 per share, for a total transaction of $206,885.50. Following the purchase, the chief executive officer now owns 538,965 shares of the company’s stock, valued at approximately $5,686,080.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

A hedge fund recently raised its stake in Concert Pharmaceuticals stock. Dimensional Fund Advisors LP boosted its position in shares of Concert Pharmaceuticals Inc. (NASDAQ:CNCE) by 405.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 224,348 shares of the company’s stock after buying an additional 179,998 shares during the period. Dimensional Fund Advisors LP owned 1.02% of Concert Pharmaceuticals worth $4,256,000 as of its most recent filing with the SEC.

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.